| Identification | Back Directory | [Name]
Benzeneacetic acid, 4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)-4-pyridinyl]methyl]- | [CAS]
1606974-33-7 | [Synonyms]
BPN14770
Benzeneacetic acid, 4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)-4-pyridinyl]methyl]- | [Molecular Formula]
C21H15ClF3NO2 | [MDL Number]
MFCD32067916 | [MOL File]
1606974-33-7.mol | [Molecular Weight]
405.8 |
| Chemical Properties | Back Directory | [Boiling point ]
514.4±50.0 °C(Predicted) | [density ]
1.351±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 260 mg/mL (640.71 mM) | [form ]
Solid | [pka]
4.27±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Zatolmilast is a selective phosphodiesterase 4D (PDE4D) allosteric inhibitor for the treatment of fragile X syndrome and other brain disorders. | [in vivo]
Zatolmilast increases brain cAMP, increases phosphorylation of CREB and increases production of brain-derived neurotrophic factor (BDNF) in hippocampus[1].
?
Zatolmilast (0.1-30 mg/kg; p.o.; 24 hours) provides cognitive benefit in the mouse novel object recognition (NOR) at doses above 0.3 mg/kg[2]. | Animal Model: | C57Bl6 mice[2] | | Dosage: | 0.1, 0.3, 1, 3, 10, 30 mg/kg | | Administration: | p.o.; 24?hours | | Result: | Significantly improved novel object discrimination at doses above 0.3 mg/kg. |
| [IC 50]
PDE4D3: 7.4 nM (IC50); PDE4D7: 7.8 nM (IC50) |
|
|